RxDoctor Payments Data

Millian Okafor

Psychiatric/Mental Health · Orlando, FLNPI 1114403631

Payments from drug & device makers

$3,102in general payments, 2019–2025

Across 152 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$966
  • Otsuka America Pharmaceutical, Inc.$558
  • Vanda Pharmaceuticals Inc.$308
  • Johnson & Johnson$260
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$190
  • Lundbeck LLC$161
  • plus $661 from 10 others

What the payments were for

  • Food & beverage$3,05598%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,102 in reported general payments places this provider in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$8,548
Medicare patients
29
Services billed
90

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LybalviOlanzapine/Samidorphan Malate14$22,783
RexultiBrexpiprazole12$16,961
Clozapine13$1,490
Desvenlafaxine Succinate ErDesvenlafaxine Succinate13$891
Quetiapine Fumarate29$783
Naltrexone Hcl11$631
Sertraline Hcl67$612
Escitalopram Oxalate60$599
Aripiprazole35$586
Trazodone Hcl61$469
Mirtazapine14$464
Divalproex Sodium ErDivalproex Sodium19$445
Lamotrigine33$397
Bupropion Hcl SrBupropion Hcl18$390
Haloperidol13$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Lybalvi$113$22,78314 claims
Otsuka America Pharmaceutical, Inc.Rexulti$558$16,96112 claims
Lilly USA, LLCOlanzapine$46$27813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →